COCP — Cocrystal Pharma Balance Sheet
0.000.00%
- $15.46m
- $5.60m
Annual balance sheet for Cocrystal Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 33 | 58.7 | 37.1 | 26.4 | 9.86 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.556 | 0 | 0.716 | 0.89 | 1.22 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 34 | 59.3 | 40.2 | 29.1 | 11.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.09 | 0.931 | 0.616 | 2.12 | 1.85 |
Net Goodwill | |||||
Long Term Investments | |||||
Total Assets | 54.2 | 79.4 | 40.8 | 31.3 | 13.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.36 | 1.54 | 1.22 | 3.26 | 2.43 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.74 | 1.84 | 1.27 | 4.88 | 3.93 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 52.5 | 77.5 | 39.6 | 26.4 | 9.52 |
Total Liabilities & Shareholders' Equity | 54.2 | 79.4 | 40.8 | 31.3 | 13.5 |
Total Common Shares Outstanding |